A prospective, randomized, multi-center comparative 2-arm trial of efficacy and safety of zoledronic acid (every 3-months vs. every 4 weeks) beyond approximately 1 year of treatment with zoledronic acid in patients with bone lesions from breast cancer.

Trial Profile

A prospective, randomized, multi-center comparative 2-arm trial of efficacy and safety of zoledronic acid (every 3-months vs. every 4 weeks) beyond approximately 1 year of treatment with zoledronic acid in patients with bone lesions from breast cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 May 2016

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Advanced breast cancer; Bone metastases
  • Focus Therapeutic Use
  • Acronyms ZOOM
  • Sponsors Novartis
  • Most Recent Events

    • 15 May 2013 Results published in Lancet Oncology.
    • 20 Jun 2012 Actual patient number changed to 425 as reported in results presented at ASCO 2012.
    • 05 Jun 2012 Primary endpoint 'Skeletal-event-rate' has been met; the experimental treatment regimen was found to be non-inferior to conventional treatment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top